| NCT ID | NCT05567744 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Wisconsin, Madison |
| Condition | Cerebral Autosomal Dominant Ateriopathy With Subcortical Infarcts and Leukoencephalopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2022-06-03 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,500 participants in total. It began in 2022-06-03 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done in order to create a registry (list) of people interested in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) research. It may be that you have a family member or other loved one with CADASIL, or that you may have CADASIL or are at risk. Participation means that your name will be added to a list of people who will be invited to participate in future research studies on CADASIL. Participants must be 18 years or older, and will remain on the registry until they request to be removed.
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * have a loved one or a family member with CADASIL, or are at-risk for CADASIL themselves Exclusion Criteria: * Under 18 years of age
Contact & Investigator
Jane Paulsen, PhD
PRINCIPAL INVESTIGATOR
University of Wisconsin, Madison
Frequently Asked Questions
Who can join the NCT05567744 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Cerebral Autosomal Dominant Ateriopathy With Subcortical Infarcts and Leukoencephalopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05567744 currently recruiting?
Yes, NCT05567744 is actively recruiting participants. Contact the research team at info@cadasil-consortium.org for enrollment information.
Where is the NCT05567744 trial being conducted?
This trial is being conducted at Madison, United States.
Who is sponsoring the NCT05567744 clinical trial?
NCT05567744 is sponsored by University of Wisconsin, Madison. The principal investigator is Jane Paulsen, PhD at University of Wisconsin, Madison. The trial plans to enroll 2,500 participants.